Figure 2From: Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathyChanges in the foveal thickness at the end of the third year in each treatment schedule. The white and shaded bars indicate changes from the baseline and the 2-year values, respectively. PRN = pro re nata. *P = 0.01; †P = 0.03.Back to article page